Stockscreener 앱 받기
0.308
0.98%
0.003
시간 외 거래:
.30
-0.008
-2.60%
전일 마감가:
$0.305
열려 있는:
$0.305
하루 거래량:
190.00K
Relative Volume:
0.31
시가총액:
$16.67M
수익:
$20.97M
순이익/손실:
$-118.51M
주가수익비율:
-0.1495
EPS:
-2.06
순현금흐름:
$-94.45M
1주 성능:
+2.33%
1개월 성능:
-14.44%
6개월 성능:
-66.15%
1년 성능:
-81.67%
1일 변동 폭
$0.30
$0.315
1주일 범위
$0.2721
$0.315
52주 변동 폭
$0.24
$1.68
Cara Therapeutics Inc Stock (CARA) Company Profile
명칭
Cara Therapeutics Inc
전화
203-406-3700
주소
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-03-08 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-03-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-11-01 | 재개 | Canaccord Genuity | Buy |
| 2021-08-03 | 개시 | JP Morgan | Neutral |
| 2020-04-21 | 재확인 | H.C. Wainwright | Buy |
| 2019-08-12 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-29 | 재확인 | Laidlaw | Buy |
| 2019-02-06 | 재개 | Jefferies | Buy |
| 2019-01-15 | 개시 | BofA/Merrill | Neutral |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-13 | 개시 | Jefferies | Buy |
| 2018-08-08 | 재확인 | Stifel | Buy |
| 2018-06-28 | 재확인 | H.C. Wainwright | Buy |
| 2018-03-12 | 재개 | H.C. Wainwright | Buy |
| 2018-02-12 | 업그레이드 | Janney | Neutral → Buy |
| 2018-01-19 | 개시 | Seaport Global Securities | Buy |
| 2017-06-30 | 다운그레이드 | Janney | Buy → Neutral |
| 2017-06-30 | 재확인 | Laidlaw | Buy |
| 2017-06-30 | 재확인 | Stifel | Buy |
| 2017-03-28 | 재확인 | H.C. Wainwright | Buy |
| 2017-03-28 | 재확인 | Laidlaw | Buy |
| 2017-03-10 | 재확인 | Laidlaw | Buy |
| 2016-10-13 | 개시 | H.C. Wainwright | Buy |
| 2016-08-08 | 재확인 | Needham | Buy |
모두보기
Cara Therapeutics Inc 주식(CARA)의 최신 뉴스
Market Recap: Cara Therapeutics Inc (CARA)’s Positive Momentum, Closing at 0.31 - The Dwinnex
Stock Analysts’ New Coverage for September 26th (AINC, AIRI, APTO, BLK, CARA, CBOE, CLLS, CME, CMLS, CTLT) - Defense World
Cara Therapeutics (NASDAQ:CARA) Receives New Coverage from Analysts at StockNews.com - Defense World
Layoff Tracker: Bluebird Bio to Cut 25% of Workforce and More News - BioSpace
A closer look at Cara Therapeutics Inc (CARA) is warranted - US Post News
Pruritus Clinical Trials 2024: FDA Approvals, Medication, - openPR
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Aclaris Therapeutics neutral rating reiterated on phase 2a trial - Investing.com
Federated Hermes Inc. Acquires Shares of 670,468 Sage Therapeutics, Inc. (NASDAQ:SAGE) - Defense World
Carmat launches capital increase, stock plummets - Marketscreener.com
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Sage Therapeutics, Inc. of Class Action Lawsuit and Upcoming DeadlinesSAGE - PR Newswire
What technical indicators reveal about CARA stock - US Post News
The time has not yet come to remove your chips from the table: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA)’s Day in Review: Closing at 0.26, Down by -2.85 - The Dwinnex
CARA’s Stock Market Adventure: -62.18% YTD Growth Amidst Volatility - The InvestChronicle
How to interpret Cara Therapeutics Inc (CARA)’s stock chart patterns - US Post News
Pruritus Therapeutics Market Competition & Segment Analysis – Actavis Plc, Amgen Inc., Bristol-Myers Squibb, Cara Therapeutics, Cipla – Cauverynews - Cauverynews
Metric Deep Dive: Understanding Cara Therapeutics Inc (CARA) Through its Ratios - The Dwinnex
Pruritus Pipeline Analysis 2024: FDA Approvals and Emerging - openPR
Does Cara Therapeutics Inc (CARA) offer a good opportunity for investors? - SETE News
Cara Therapeutics (NASDAQ:CARA) Now Covered by Analysts at StockNews.com - Defense World
Following more layoffs, Stamford’s Cara Therapeutics considers ‘strategic alternatives,’ including dissolving company - Hartford Business Journal
Analysts review Cara Therapeutics Inc’s rating - Knox Daily
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Rating of “Hold” by Brokerages - Defense World
Vanguard Group Inc. Reduces Position in Cara Therapeutics, Inc. (NASDAQ:CARA) - Defense World
CARA Stock Earnings: Cara Therapeutics Misses EPS, Misses Revenue for Q2 2024 - InvestorPlace
Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World
Cara Therapeutics (NASDAQ:CARA) Issues Quarterly Earnings Results, Misses Estimates By $0.10 EPS - Defense World
Cara: Q2 Earnings Snapshot - San Antonio Express-News
Cara: Q2 Earnings Snapshot - The Washington Post
Cara: Q2 Earnings Snapshot - Milton Daily Standard
Cara: Q2 Earnings Snapshot - Thehour.com
Investing in Cara Therapeutics Inc (CARA) Is Getting More Attractive - Knox Daily
Understanding the Risks of Investing in Gain Therapeutics Inc (GANX) - Knox Daily
Cara Therapeutics receives Nasdaq compliance extension - Investing.com India
Cara Therapeutics CEO sells over $1,400 in stock - Investing.com India
Cara Therapeutics receives Nasdaq compliance extension By Investing.com - Investing.com Australia
Cara Therapeutics CEO sells over $1,400 in stock - Investing.com
Cara Therapeutics receives Nasdaq compliance extension - Investing.com
Cara Therapeutics, Inc. (NASDAQ:CARA) Given Consensus Recommendation of “Hold” by Brokerages - Defense World
Taking the lead: Cara Therapeutics Inc (CARA) - SETE News
Cara Therapeutics Inc (CARA) deserves deeper analysis - US Post News
CT-based bioscience firm Cara Therapeutics eliminates most of workforce, filing indicates - CT Insider
5 Biotechs That May Surge On Takeovers - Investopedia
Medical Marijuana Market Growth Drivers | Cannabis Sativa, Inc.; Cara Therapeutics Inc., Inc.; United Cannabis Corporation – Economica - Economica
Cara Therapeutics (NASDAQ:CARA) Share Price Passes Below 200 Day Moving Average of $0.65 - Defense World
Recent Insider Activity Could Benefit Cara Therapeutics Inc (CARA) - Knox Daily
Cara Therapeutics (NASDAQ:CARA) Research Coverage Started at StockNews.com - Defense World
These Cara Therapeutics Analysts Are No Longer Bullish: 'We See No Obvious Future Value Drivers' - MSN
Sarcoma Therapeutics Market Is Booming Worldwide | Agenus, Agios, Eisai - openPR
Insider Selling: Posner Christopher, Cara Therapeutics Inc [CARA] PRESIDENT AND CEO divested 3,936 shares - Knox Daily
Cara Therapeutics Inc (CARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.05%
4.86%
자본화:
|
볼륨(24시간):